The FDA has proposed loosening its rules regarding informed consent to make it easier for researchers to enroll patients in clinical trials.
A new proposal from the agency would allow institutional review boards (IRBs) to amend or waive entirely informed consent under some circumstances, as long as the intervention under investigation poses “no more than minimal risk to human research participants,” according to the FDA.
“Obtaining informed consent from those who volunteer to